Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

26.64 -0.71 (-2.58%)

Streaming Delayed Price Updated: 1:36 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? ↗

September 09, 2024

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the...

Via Benzinga

Roivant Provides Update on Graves’ Disease Development Program

September 09, 2024

From Roivant Sciences

Via GlobeNewswire

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗

August 29, 2024

Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.

Via Investor's Business Daily

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

August 08, 2024

From Roivant Sciences

Via GlobeNewswire

Evaluating Roivant Sciences: Insights From 6 Financial Analysts ↗

June 18, 2024

Via Benzinga

The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts ↗

May 31, 2024

Via Benzinga

Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know ↗

April 22, 2024

Via Benzinga

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

July 25, 2024

From Roivant Sciences

Via GlobeNewswire

ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 ↗

May 30, 2024

ROIV stock results show that Roivant Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.

Via InvestorPlace

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 30, 2024

From Roivant Sciences

Via GlobeNewswire

Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On? ↗

May 22, 2024

BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million.

Via Benzinga

Where Roivant Sciences Stands With Analysts ↗

March 25, 2024

Via Benzinga

The Analyst Landscape: 4 Takes On Roivant Sciences ↗

February 14, 2024

Via Benzinga

Roivant Sciences Earnings Preview ↗

February 12, 2024

Via Benzinga

Assessing Roivant Sciences: Insights From 5 Financial Analysts ↗

January 02, 2024

Via Benzinga

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

May 16, 2024

From Roivant Sciences

Via GlobeNewswire

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare ↗

May 07, 2024

Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.

Via InvestorPlace

3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 ↗

May 01, 2024

Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.

Via InvestorPlace

Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study ↗

April 02, 2024

Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure...

Via Benzinga

Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study ↗

April 02, 2024

The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira.

Via Investor's Business Daily

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

April 02, 2024

From Roivant Sciences

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

March 29, 2024

Via Benzinga

Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase ↗

March 27, 2024

Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading.

Via Investor's Business Daily

5 Value Stocks In The Healthcare Sector ↗

February 19, 2024

Via Benzinga

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

February 13, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

January 30, 2024

From Roivant Sciences

Via GlobeNewswire

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space ↗

January 12, 2024

The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.

Via Investor's Business Daily

Earnings Scheduled For February 13, 2024 ↗

February 13, 2024

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.

Via Benzinga

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations ↗

January 10, 2024

Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to

Via Benzinga

Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% ↗

December 21, 2023

Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Delivering useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/pages/Cabling-Installation-and-Maintenance/298118662118

https://www.instagram.com/cim_magazine/

https://www.linkedin.com/company/3962332

http://twitter.com/CABLINGMAG

Affiliated Brands

DATA CENTER FRONTIER

ISE

LIGHTWAVE

DIGITAL INFRASTRUCTURE GROUP

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions